Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is well-positioned for growth, primarily due to the strong performance of its lead therapy, cabozantinib, which has established itself as a leading treatment for renal cell carcinoma (RCC) and is expanding into neuroendocrine tumors (NETs) following positive data from the CABINET study. Furthermore, the encouraging results associated with zanzalintinib combined with atezolizumab demonstrate a statistically significant improvement in overall survival, enhancing Exelixis's portfolio and future prospects. The company's focus on expanding its treatment indications and improving patient outcomes, supported by strong long-term data and market positions, suggests a robust growth trajectory.

Bears say

Exelixis Inc. faces a significant patent cliff anticipated by 2031, with projections suggesting an 80% decline in revenues by 2032, which sharply exceeds current market expectations of a 68% drop. The company is also grappling with competitive risks, including erosion of market share for its key drug cabozantinib in renal cell carcinoma (RCC) and disappointing potential for its other treatment indications, which could adversely affect future performance. Furthermore, the potential for approval delays and developmental risks associated with the drug zanzalintinib introduce additional uncertainties that compound the outlook for Exelixis's stock.

Exelixis (EXEL) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 19 analysts, Exelixis (EXEL) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.